Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Unknown 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 5Gastrointestinal 2Other hematologic neoplasm 1Lymphoid 1Endocrine 1Breast 1

Conditions

Neuroendocrine Tumors 52Thyroid Neoplasms 19Thyroid Cancer, Papillary 16Carcinoma, Neuroendocrine 16Pheochromocytoma 11Adrenocortical Carcinoma 11Thyroid Carcinoma, Anaplastic 10Gastro-enteropancreatic neuroendocrine tumor 10Small Cell Lung Carcinoma 9Paraganglioma 9Multiple Endocrine Neoplasia Type 1 9Pituitary Neoplasms 8Lung Neoplasms 8Adenoma, Islet Cell 8Sarcoma 7Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Carcinoma, Medullary 6Adenocarcinoma, Follicular 6Colorectal Neoplasms 5Central Nervous System Neoplasms 5Carcinoma, Renal Cell 5Carcinoma, Merkel Cell 5Carcinoid Tumor 5Somatostatinoma 4Pancreatic Neoplasms 4Neuroblastoma 4Neoplasm Metastasis 4Cholangiocarcinoma 4Carcinoma, Hepatocellular 4

Interventions

relacorilant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Diabetes Mellitus, Type 2 × Endocrine × Clear all
NCT03604198 2026-04-21

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Corcept Therapeutics

Phase 2 Active not recruiting
125 enrolled
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Cushing Syndrome, Diabetes Mellitus, Type 2, Hypertension, Adrenocortical Carcinoma, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡